Tag Archives: Cancer research

GRAPHENE strips as “flying carpets” deliver cancer cure drugs

GRAPHENE – New Research
That May Help Mesothelioma Victims


An international team of researchers has developed a drug delivery technique that utilizes GRAPHENE strips as “flying carpets” to deliver drugs to cancer cells.  The technique was found to perform better well when tested in a mouse model targeting a human lung cancer tumor.

Graphene Tests Succeed

GRAPHENE successfully proved itself in lab tests against six kinds of cancer cells. Flaked Graphene oxide preferentially hits these cancers right in the stem cells.

The Graphene strip works when a cancer drug treatment can be physically integrated and bound to it because of similar molecular structures of Graphene and the drug.  So, various drug treatments can be attached to the surface of the Graphene by a combination of amino acids known as peptides.

Dr. Parkish Gill, on behalf of the Mesothelioma Research Foundation of America will determine if there is a way to apply and proceed with his non-chemotherapy treatments using the Graphene strip technique.

Click this link to read the complete story

New Drug Targets Cancer Caused By Asbestos

May 26, 2014

Mesothelioma lung cancer can come to those persons who loved, and simply hugged their parent who worked around asbestos.  For example, now at age 45, Heather Von St. James recalls her father working as a building demolition employee around materials containing asbestos.  He would return home each day thoroughly covered by dirt and dust. She remembers how much she enjoyed hugging her father each night.mesothelioma-studies

By age 36, Heather was diagnosed with mesothelioma, the deadly yet to be cured cancer connected with exposure to asbestos particles.  Mesothelioma can take decades to develop and it often kills within months after symptoms appear. Heather was a new mother to a 3-month-old daughter, and she was told her only chance to live was by having a lung removed.

In 2013, more than 107,000 people died worldwide from mesothelioma.  However, Heather opted for the surgery instead, and removed the disease in time to stay alive.   According to Ms. St. James, “There’s a lot of people who don’t.”

Fortunately for other people with mesothelioma, or those that will discover they have the deadly disease, a new wave of drugs developed and being tested are giving new hope that mesothelioma cancer may be slowed or stopped.  Drug researchers, like Verastem Inc. (VSTM), GlaxoSmithKline Plc (GSK), and Dr. Parkash Gill of the USC Norris Comprehensive Cancer Center have announced that they are testing new cancer fighting drugs.

According to Dean Fennell, a lead researcher doing a trial study with a new drug by Verastem:

“[Mesothelioma] is not a curable cancer; it’s not a disease that can be wiped out completely by surgery as you see with lung cancer. Finding ways to stop that process or slow it down can have big implications for patient survival.”

Unlike lung cancers, Mesothelioma affects the cell tissues that cover the lungs.  It can also affect the tissues around the heart and abdominal organs.  Like all cancers, mesothelioma is treated by doctors with cutting the cancer tissue out, or irradiating it, but both methods sometimes have dangerous side effects.

New Drugs Offer New Hope to Replace Old Treatments

Verastem (based out of Cambridge, Massachusetts) has developed a drug (VS-6063) that is now in late-stage human testing. Consecutively, Glaxo (based out of London) has a compound that is being tried in combination with another product in an early-stage study. The drugs from these two companies each target an enzyme involved in cell movement that permits the cancer to spread.

The enzyme is a key marker of aggressive cancers and is overabundant in many tumors that spread quickly. Also, patients with an inactive gene called Neurofibromatosis 2 (NF2) respond well to the test drugs being developed where nearly half of mesothelioma patients have inactive NF2s.

In the U.S. and Europe, the VS-6063 treatment has been granted orphan drug status.  This means that Verastem with their VS-6063 product is given seven (7) years of exclusive marketing.  A Bloomberg report states that according to four (4) analysts, the VS-6063 drug could possibly generate $450 million in sales by 2019 if the product is cleared for public use.

Earliest Stage

Defactinib is the medicine that targets early stage cancer stem cells.  These are considered to be theorigin of the cancer and frequently are resistant to existing therapies.   The cancer stem cells for mesothelioma are known to be particularly resistant to chemotherapy.

Now, Mr. Dean Fennell does not have an economic connection with Verastem, nor is he a paid consultant to the company.  And yet, Mr. Fennell (who is chairman of thoracic medical oncology at the University of Leicester in England) stated during an interview:

“The hope is we can suppress the cancer in such a way that it becomes a more chronic disease, rather than have a disease that’s going to progress relentlessly and kill the patient”

Verastem with a market value of about $215 million is developing the drug assisted by several renowned pharmaceutical companies providing guidance. The development team includes former Genzyme Corp. CEO Henri Termeer; Human Genome Project leader Eric Lander; and Phillip Sharp, a Nobel laureate at Biogen Idec Inc.

Other Drug Combinations

Under a license from Pfizer Inc., AstraZeneca Plc of London is testing a drug called tremelimumab, on mesothelioma in a mid-stage trial. The treatment works differently from the other developmental drugs in that it helps the patient’s immune system to recognize and kill cancer cells.  According to

Carolyn Buser-Doepner (VP for tumor signaling at Glaxo, the U.K.’s biggest drugmaker), there are plans to combine a new drug GSK2256098 with some other medicines to potentially make cancer treatments more effective.  In one early-stage trial, it will be paired up with Glaxo’s Mekinist, which is approved for melanoma.  She said, “The pre-clinical data are very encouraging. We’re very excited about it.”

Boehringer’s Drug

A fourth drug, nintedanib from Germany’s Boehringer Ingelheim GmbH, is in early-stage testing for mesothelioma, according to a spokesman. Unlike the previous mentioned medicines, this one works by targeting proteins directly related to the formation of blood vessels that feed tumors.

According to the director of research at the British Lung Foundation, Noel Snell, the kind of research studies most likely to yield improvements in cancer care are those that investigate the nature of the disease itself.  Still, treatments being tested today on mesothelioma are most encouraging.

Snell said in a statement:

“It is shameful that this kind of fundamental research remains so drastically underfunded, and that the number of trials available for mesothelioma patients is still dwarfed so dramatically by the number available to other cancer patients.”

Dr. Gill and EphB4 Treatment

For several years, Dr. Parkash Gill of the USC Norris Comprehensive Cancer Center has proceeded with Phase I Clinical Trials with the new cancer fighting drug Eph-B4 made available to qualifying mesothelioma patients. With generous support from the Mesothelioma Research
Foundation of America
, the initial Phase I Trial Eph-B4 has been available to newly diagnosed patients who have not Ask Dr. Gill about the most recent clinical trials avaialbleundergone any conventional lung cancer treatment options, as well as those patients who have exhausted all other treatment options such as surgery and chemotherapy.

The results of these recent clinical trials have truly been exciting as Dr. Gill reports that Eph-B4 is showing great promise as a solo treatment, or in conjunction with other drugs like Alimta, Cisplatin and Carboplatin.

The research of Dr. Gill, in conjunction with similar studies by other Oncologists, have improved the understanding among Primary Care physicians about the detection process, and given them better options to offer patients with lung cancer including mesothelioma.

Eph-B4 as a Better Treatment

Treatments have also gotten better because we now understand two principles: a)molecular changes in lung cancer with very specific mutations; and b)medication (like Eph-B4) that is specific to addressing the treatment of only one cellular abnormality.

As Dr. Gill with the Mesothelioma Research Foundation of America continues the goal to make mesothelioma a disease of the past, our understanding of the human body immune system has also improved.    From this we have Eph-B4, an immune specific treatment that assists a patient with lung cancer to live longer with fewer side effects.

His studies have contributed to the evolution of mesothelioma cancer research over the last decade.  Collectively, researchers are producing a canonical story in which the range of research works has grown a consensus among recognized oncologists and Primary Care physicians of a “great” or “major” break through with the two principles mentioned above.  Basically, we can now identify subsets of cancer in a patient at the molecular level and bring a retardant treatment (immunity) to that cancer in those patients.  And this observation continues to this day to be repeated by many research projects.  More than ever before, researchers continue to identify specific cancer mutations and use similar drugs to shut down these cancers and improve patient survival.

Asbestos: The Miracle Fiber That Kills

Asbestos was named the “miracle fiber,” but has become the topic and issue of many lawsuits claiming losses as well as damages from illness caused by asbestos products.  It was commonly used in building materials such as insulation for years because it was cheap, abundant and heat-resistant.

Many countries have banned asbestos mining.  However, the World Health Organization estimates that as many as 125 million people worldwide continue to be exposed to asbestos either at work or in their homes because it continues to be mined and made into  products from in RussiaChina and India.

Unfortunately, mesothelioma cancer can lay dormant for as long as 50 years before spreading, which explains why rates have risen long after many countries have banned the asbestos.

New cases of mesothelioma cancer in the United Kingdom, where asbestos was restricted starting in the 1980s and outlawed fully in 2006, were 2,125 in 2012.  These numbers are expected to peak in 2015.  In the United States, the number of new cancer cases has been stable, hovering around 3,000 per year since 2000.  This stability was expected because of extensive efforts put into public education.  Still, a complete ban of Asbestos in the U.S. was overturned in the courts.  One of the world’s largest asbestos exporters, Canada, closed its remaining mines in 2011.

An Asian Asbestos Mesothelioma Cancer ‘Tsunami’

In Japan, asbestos was banned in 2006, the Japanese government pays the full cost of treatment for related illnesses, and rate of new cases of cancer are predicted to continue rising until 2027.  The director of a World Health Organization occupational health group, Ken Takahashi, has warned Asian governments to prepare themselves for an “asbestos tsunami.”

Again, Dean Fennell reminds us:

 “In the early ’70s, this was an incredibly rare disease. Now my clinic is full of patients with mesothelioma. Because the rates are increasing, we have a real need now to identify effective treatment.”

A cure for mesothelioma can not be found fast enough.  Still, there are survivors like Heather Von St. James, who breaths with great effort during Minnesota winters with her one remaining lung, and she volunteers her time to be a coach to other mesothelioma patients.   By her personal experience with mesothelioma, she wants other victims of mesothelioma to understand:

 “If they can keep it under control,
that’s the first hope.”


The Truth about Mesothelioma Symptoms

Mesothelioma symptoms can vary from patient to patient.

mesothelioma symptomsOne can make a valiant effort to possibly live through this dreaded disease by trying to understand its symptoms and how to detect it as early as possible.

What exactly is mesothelioma?

This is a type of cancer that affects the lining of various internal organs; including the lungs, heart, and abdominal cavity. This type of cancer is sometimes caused by exposure to a type of insulating material called asbestos.

Mesothelioma symptoms may not start for years, or even decades, after one is exposed to this toxic material.

How can a person tell if they have mesothelioma symptoms?

Only a doctor can diagnose mesothelioma. Mesothelioma symptoms are varied and they can often be confused with symptoms of many other illnesses. Mesothelioma symptoms may include shortness of breath, a mass in the abdominal region, fever, night sweats, a general feeling of illness, and many other symptoms that should be discussed with a medical professional. Often mesothelioma attorneys educate their clients that some of the symptoms they may have believed to be something else are actually attributable to this illness.

Why is it so hard to diagnose mesothelioma symptomss?

Mesothelioma symptoms can be extremely inconsistent, which can lead to a host of incorrect diagnoses and misunderstandings.

Far too often a person will have no mesothelioma symptoms for years after exposure, which is due to the fact that mesothelioma grows slowly within a person’s body. This can lead to potential treatment time not being utilized.

What can be done about mesothelioma?

Medical professionals are constantly working on newer and better ways to treat every kind of illness, but thus far there have been few breakthroughs. Some of the most promising discoveries are found in the research and clinical studies by Dr. Gill.  In recent years, a lot of non-medical work has been done with regard to this illness like mesothelioma attorneys mounting cases against the asbestos manufacturing industry, which hid vital information about the potential dangers of asbestos exposure. Tens of millions of individuals may have been exposed, which could potentially lead to large numbers of mesothelioma cases.

Where can I find more information about mesothelioma symptoms?

Additional mesothelioma symptoms information is available here and at www.mesorfa.org our central research center web site.

Related Mesothelioma Articles

PhRMA Golf Invitational raises $11,000 for mesothelioma cancer cure research

October 29, 2012

PhRMA Golf Invitational

The Mesothelioma Research Foundation of America was blessed with a sixth and final event to finish our 2012 season of  fundraising efforts. The Pharmaceutical Research and Manufacturers of America hosted a Golf Invitational at the Napa Valley Country Club, and with the assistance and support of the California State Building and Construction Trades the Mesothelioma Research Foundation of America was the benefactor of the event! The event’s proceeds totaled nearly $11,000, of which 100% will go towards research in finding a cure for mesothelioma!

Read more…

Three Studies in Pleural Mesothelioma Cancer – August 2012

Mesothelioma Cancer Research and Clinical Studies

visceral pleura parietal pleura

Mesothelioma Cancer Research Study #1:

 “Solitary (localized) pleural mesothelioma: A light- and electron-microscopic study”

in American Journal of Surgical Pathology

 Abstract – Six solitary (localized) pleural mesotheliomas were studied by light and electron microscopy. All the lesions were benign and were composed mainly of fibrous tissue of variable cellularity with or without cystic spaces lined by round cells. The lining cells of the cysts and the adjoining round plump cells were interpreted as true neoplastic cells of the fibroblast type. Results of light- and electron-microscopic study of human mesothelial cells and fetal mesothelial cells of rats were compared. The cytoplasmic organelles of the tumor cells were generally scanty, though rough endoplasmic reticulum, sparse mitochondria, intracellular bundles of fibrils, and numerous polysomes were seen.

Some tumor cells had junctional apparatus and basement membranes and showed inter-digitation of the plasma membrane. These cells lined the cystic spaces irregularly and also proliferated into the surrounding fibrous tissue, where they assumed a spindle shape and resembled fibroblasts. Ultra structurally, the tumor cells were similar to mesothelial and stromal cells of fetal rat pleura. We speculated that the solitary (localized) mesotheliomas were probably derived from coelomic epithelium and that tumor cells remained un-differentiated or revealed minimal differentiation toward mesothelial cells.

Mesothelioma Cancer Research Study #2

“Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis”

in Cytopathology Volume 11, Issue 1, Feb 2000

Abstract – Anti-CEA, anti-vimentin, CAM5.2, BerEp4, Leu-M1 and anti-EMA were applied to effusions from 36 mesotheliomas, 53 adenocarcinomas and 24 reactive mesothelial proliferations.

Stepwise logistic regression analysis selected three criteria of major importance for distinguishing between adenocarcinoma and mesothelioma: BerEp4, CEA and EMA accentuated at the cell membrane (mEMA), these three being of similar diagnostic value. The pattern BerEp4−, CEA− and mEMA+ was fully predictive for mesothelioma (sensitivity 47%), whereas the opposite pattern was fully predictive for adenocarcinoma (sensitivity 80%). Only EMA seemed to distinguish between mesotheliosis and mesothelioma. Comparison of reactivity in cytological and histological material from the same mesotheliomas showed similar staining frequencies for CEA and CAM5.2, with some random variation for Leu-M1 and EMA, whereas vimentin and BerEp4 reactivity was more frequent in cytological specimens.

Mesothelioma Cancer Research Study #3

“A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma”

– Sterman DH, Molnar-Kimber K, Iyengar T, Chang M, Lanuti M, Amin KM, Pierce BK, Kang E, Treat J, Recio A, Litzky L, Wilson JM, Kaiser LR, Albelda SM. – Cancer Gene Ther. 2000 Dec;7(12):1511-8. 

Abstract – One of the primary limitations of adenoviral (Ad) -mediated gene therapy is the generation of anti-Ad inflammatory responses that can induce clinical toxicity and impair gene transfer efficacy. The effects of immunosuppression on these inflammatory responses, transgene expression, and toxicity have not yet been systematically examined in humans undergoing Ad-based gene therapy trials. We therefore conducted a pilot study investigating the use of systemic corticosteroids to mitigate antivector immune responses. In a previous phase I clinical trial, we demonstrated that Ad-mediated intrapleural delivery of the herpes simplex virus thymidine kinase gene (HSVtk) to patients with mesothelioma resulted in significant, but relatively superficial, HSVtk gene transfer and marked anti-Ad humoral and cellular immune responses. When a similar group of patients was treated with Ad.HSVtk and a brief course of corticosteroids, decreased clinical inflammatory responses were seen, but there was no demonstrable inhibition of anti -Ad antibody production or Ad-induced peripheral blood mononuclear cell activation. Corticosteroid administration also had no apparent effect on the presence of intratumoral gene transfer. Although limited by the small numbers of patients studied, our data suggest that systemic administration of steroids in the context of Ad-based gene delivery may limit acute clinical toxicity, but may not inhibit cellular and humoral responses to Ad vectors.

Mesothelioma – A Quick Short Introduction

What Is Mesothelioma?

Mesothelioma is a rare cancer that occurs in the tissue covering the stomach and bowels (peritoneal tissue) or in the tissue covering the outside surface of the lung (pleural tissue). 90% of the cases of Malignant Mesothelioma are caused by exposure to Asbestos.

What Is Asbestos?

Asbestos is a silicate mineral made up of masses of tiny fibers that are as strong as steel and are highly resistant to heat and chemicals. Fibers of Asbestos are inhaled or swallowed and are able to penetrate to the outside surface of the bowel or to the outside surface of the lung where they become trapped. These trapped fibers can cause a reaction that leads to Mesothelioma Cancer. Mesothelioma symptoms may not appear until about 20 or 40 years from first exposure to airborne Asbestos fibers.

Mesothelioma Treatments

Mesothelioma treatments include radiation to shrink cancer tissue or cells, chemotherapy to stop the reproduction of cancer cells, photodynamic therapy and some times, surgery to remove cancerous tissue.  There also some progressive Clinical Trials offering  the hope of a cure found in their research for new solutions.  Clinical trials are available to qualified volunteers.

You Are Entitled To Compensation!

People,  who are faced with Mesothelioma Diagnosis, are entitled to compensation from the manufacturers of any asbestos-containing product to which they were exposed in sufficient quantities to cause disease.  You can discover a qualified Mesothelioma lawyer on the Internet.   Be sure to evaluate and consider the success case references when looking for counsel and representation.

A List of Studies on Mesothelioma and Chromosomal Abberrations

Study #1

Specificity of asbestos-induced chromosomal aberrations in short-term cultured human mesothelial cells

Cancer Genetics and Cytogenetics
Volume 41, Issue 1, August 1989, Pages 33-39
by Kenth Olofssona and Joachim Mark
Department of Pathology and Cytogenetics, Central Hospital, Skvde, Sweden

Abstract – Short-term cultured normal human mesothelial cells were exposed for 48 hours to three different asbestos compounds, crocidiolite, chrysotile, and amosite. In the concentration used (0.01 mg/ml) all three asbestiform minerals caused, within a few days, a significant increase of cells showing numerical and/or structural abnormalities. The abnormalities were analyzed in detail using banding techniques. The results were compared with the cytogenetic observations in 52 published cases of mesotheliomas. This comparison revealed only a few similarities as regards numerical deviations. The structural rearrangements in asbestos-exposed cultures, however, in many instances involved chromosome types and chromosome regions preferentially affected in mesotheliomas.

Study #2

Recovery of ingested asbestos fibers from the gastrointestinal lymph in rats

Environmental Research Volume 22, Issue 1, June 1980, Pages 201-216
by P. Sebastien, c, R. Masse, d and J. Bignon.

Abstract – Using the transmission electron microscope, asbestos fibers have been assessed in lymph fluid collected from the thoracic lymph duct in five groups of rats previously exposed to asbestos fibers (by ingestion). Ten rats were gavaged a single dose weighing approximately 20 mg. Five were given pure UICC chrysotile A while another group of five had pure UICC crocidolite. All the rats of the chrysotile group were positive animals with recovery rate values ranging from 6.9 107 to 3 105 (90% of the fibers being recovered during the first 16 hr following the gavage). The crocidolite group had only three positive animals and lower recovery rate values of 5.7 108 to 5.6 107. A third group was fed a synthetic diet containing 1%, by weight, chrysotile with a majority of short fibers (90% below 4 m). Of the 15 rats comprising this group, 13 were positive with maximum daily recovery rates ranging from 2.1 107 to 2.1 106. A group of eight rats fed the same kind of diet but containing a higher proportion of long fibers, showed only four positive animals, however, they had higher daily recovery rates ranging from 1.9 105 to 2.1 104. No fibers were encountered in the samples of the two control rats. This study demonstrates the passage of chrysotile and crocidolite fibers across the gastrointestinal wall, with the passage rate being higher for long fibers than short ones.

Study #3

Penetration of cells by asbestos fibers

Environ Health Perspect. 1974 December; 9: 255260
by J. M. G. Davis, R. E. Bolton, and J. Garrett

Abstract – Studies on the behavior of asbestos fibers within tissues have shown that the only cells that regularly contain asbestos are macrophages and their derivatives. However, these cells actively incorporate the asbestos fibers by the process of phagocytosis, and there is little evidence of direct penetration. Examination of the gut lining after prolonged asbestos ingestion has shown no evidence of dust penetration either through or between the epithelial cells. The structure and arrangement of these cells is discussed, and it is suggested that they are exceptionally well adapted to prevent penetration by any solid material.

Study #4

Static electrification of airborne asbestos: A study of its causes, assessment and effects on deposition in the lungs of rats

American Industrial Hygiene Association Journal, Volume 42, Issue 10 October 1981, pages 711 – 721
by J. H. Vincent; W. B. Johnston; A. D. Jones; A. M. Johnston

Abstract – The paper describes a series of experiments carried out in the laboratory to investigate how asbestos fibers might become electrostatically charged during the process of being made airborne, the magnitude and polarity of the charge per fiber, and the effect on lung deposition in rats. Measurements of the penetration of fibers through an electrostatic elutriator enabled the magnitude and distribution of charge in a cloud of fibers to be quantitatively assessed. Thus it was found that a typical fiber of UICC amosite, as dispersed in a typical animal exposure chamber, carried a net charge of magnitude equivalent to about 60 electrons. The distribution of charge was bimodal, suggesting that two charging mechanisms were taking place, the main one producing net negative charge and the lesser one producing net positive charge. These were attributed to materials in the dust dispenser used and with which the fibers came into contact during dispersal. It was found that the magnitude of charge on a typical fiber could be significantly reduced by the introduction of equal numbers of positive and negative gaseous ions from an a.c. corona discharge ionizer. Finally it was found that enhancement by up to 40% of the dust deposited into the slowest clearing part of the respiratory tract of experimental rats was brought about by the electrostatic charge on the airborne fibers. The implications of this finding in the field of occupational hygiene are briefly discussed.

The JOHNS Donate $5,000 For Mesothelioma Cancer Research

Press Release
March 14, 2012

The entire staff at the Mesothelioma Research Foundation of America stops and takes a deliberate moment to recognize and send a sincere thanks to the JOHNS for their donation of $5,000 designated for mesothelioma cancer research. The JOHNS event is held annually to honor a dear deceased friend, John S. Lyons, by acknowledging today’s Labor Leader of the Year as well as raise money for cancer research and other local charities. As always, 100% of the donation received by the Foundation will go toward research into treatment options for mesothelioma cancer. We also give a special thank you to our friends at the JOHNS who made this possible. Our relationship with medical research facilities in San Diego has been made possible by the help of the San Diego County Building Trades Business Manager and JOHNS Co-Chairman, Tom Lemmon and his fellow JOHNS award recipients, Retired U.A. Local 230 Business Manager, Nico Ferrarro, and current U.A. Local 230 Business Manager Kirk Crosswhite. These good allies are at the forefront of encouraging Dr. Parkash Gill and this Foundation to continue having a nexus in San Diego, CA where Dr. Gill is actively working with a lab of researchers furthering his research into better treatment options for Mesothelioma cancer, as well as other cancers that demonstrate a response to anti-angiogenesis treatments. More about anti-angiogenesis treatments (non-chemotherapy drugs) and Dr. Gill’s research can be found at:


MesoRFA Urges Families Grieving Over The Loss Of Their Mesothelioma Patient To Support Research For A Cure

Researchers study Veglin in search of a Mesothelioma cancer cure
Researchers at MesoRFA.org

The Mesothelioma Research Foundation of America understands:

We know first-hand how horrible a mesothelioma diagnosis can be for a US Navy Veteran or an individual, and we know first-hand how hard it is for the family. Unfortunately, too many families affected by mesothelioma do not know what to do or who to call, and they simply do nothing. The Research Foundation was created to do something special through research to produce a drug that brings hope for a cure,  like Veglin.  There is also concern that many US Navy Veterans or individuals die each year from mesothelioma, because they never received proper healthcare, or the doctor simply missed the mesothelioma.

MesoRFA is working hard to be game changers for US Navy Veterans or individuals dealing with a mesothelioma diagnosis, or a family dealing with a loss of their loved one from this rare deadly disease.

Aside from US Navy Veterans, other high risk groups for mesothelioma cancer include shipyard, power plant, or oil refinery workers, plumbers, electricians, county, chemical plant, or city municipal water district workers, miners, demolition construction contractors, railroad workers, or auto brake technicians.

According to MesoRFA lead researcher and oncologist, Dr. Parkash S. Gill:

Typically the average US mesothelioma victim is about 72 years old. More often than not mesothelioma is diagnosed three, four, or even five decades after the exposure to asbestos. Regrettably mesothelioma frequently appears out of the blue. Almost all US mesothelioma victims are retired, and it’s literally the last thing they ever thought might happen to them. Most don’t exactly what mesothelioma cancer is, and it is a serious concern that hundreds of families dealing with a mesothelioma death haven’t realized that new, break through research on a cure is available for their support of future patients who will be diagnosed with this cancer.

Individuals who were exposed to asbestos and have developed symptoms of mesothelioma, lung cancer, asbestosis or another asbestos-related disease should seek a  professional medical opinion.  The Mesothelioma Research Foundation of America (a not-for-profit research organization) provides free access to our mesothelioma research team for answers to your medical questions.  Simply Ask Dr. Gil.

Mesothelioma Research Foundation of America
800-909- 6376

Mesothelioma treatment – Veglin clinical trial – phase 2 resumes

August 21, 2011

Today, Dr. Parkash Gill announced that Veglin is again being released for continued Phase 2 Clinical Trials by FDA approval. According to Gill, the studies for Veglin should be open within the month. He has completed and turned in the protocol and detail as required which will allow Phase 2 clinical studies to soon start up again on Veglin. Also, a Phase 1 clinical study on Eph B4, Dr. Gills other molecule, should be available soon.

Mesothelioma treatment cure found in Veglin - phase 2 clinical trials

Ask Dr. Gill about mesothelioma treatment cure in Veglin

Ask Dr. Gill about the upcoming study of Veglin, Phase 2 clinical trials… Click Here

Learn about Veglin at this MesoRFA link: read more…

And learn about participating in a clinical trial at these MesoRFA links: